Todd Franklin Watanabe, See Remarks at Arcutis Biotherapeutics, Inc. (ARQT), sold 2,435 shares at $15.26 ($37K) on 2023-03-06, disclosed to the SEC on 2023-03-08.
Scheduled sale ($37k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ARQT | SELL | 2025-03-20 | $21K | — | Filing → |
| ARQT | SELL | 2025-03-04 | $654K | — | Filing → |
| ARQT | SELL | 2025-02-04 | $490K | — | Filing → |